

## SUMMARY TABLE OF MEASURE CHANGES

Measure Name	Changes
Guidelines for Physician Measurement	<ul style="list-style-type: none"> <li>• Added <i>Indicators That Require the Same Data Collection Method</i> guideline to the Data Collection Methods section.</li> <li>• <i>Self-Administered Tests</i> guideline was renamed <i>Patient-Collected Samples and Biometric Values</i>; revised when patient-collected samples can be used.</li> <li>• Clarified <i>Date Specificity</i> guideline under the Medical Record Method.</li> <li>• Clarified <i>Identifying Events/Diagnoses Using Laboratory or Pharmacy Data</i> guideline under the Electronic Method.</li> <li>• <i>Using the Hybrid Method to Collect Measures With Multiple Numerator Events</i> guideline was renamed <i>Collecting Data for Measures With Multiple Numerator Events</i>, and information in the guideline was clarified.</li> <li>• Added <i>Measures That Require Results From the Most Recent Test</i> guideline under the Hybrid Method.</li> <li>• Added Uniform Bill Code Licensing Information guideline.</li> </ul>
<b>Effectiveness of Preventive Care</b>	
Guidelines for Physician Effectiveness of Care	<ul style="list-style-type: none"> <li>• No changes to these guidelines.</li> </ul>
Adult BMI Assessment	<ul style="list-style-type: none"> <li>• Clarified that documentation of &gt;99% or &lt;1% meet criteria for <i>BMI percentile</i>.</li> </ul>
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents	<ul style="list-style-type: none"> <li>• Clarified that documentation of &gt;99% or &lt;1% meet criteria for <i>BMI percentile</i>.</li> </ul>
Childhood Immunization Status	<ul style="list-style-type: none"> <li>• Revised value sets and value set names: <ul style="list-style-type: none"> <li>– For measles, mumps, rubella, hepatitis B, VZV and hepatitis A, value sets were split into two, one to identify the antigen and one to identify a history of the illness.</li> <li>– For all antigens, names for value sets containing codes that identify the antigen now include the terminology “vaccine administered.”</li> <li>– For MMR, VZV and influenza exclusions, <u>Lymphoreticular Cancer Value Set</u>, <u>Multiple Myeloma Value Set</u> and <u>Leukemia Value Set</u> were combined into a single value set: <u>Malignant Neoplasm of Lymphatic Tissue Value Set</u>.</li> <li>– <u>Hepatitis B Diagnosis Value Set</u> was renamed <u>Hepatitis B Value Set</u>.</li> <li>– <u>Immunodeficiency Value Set</u> was renamed <u>Disorders of the Immune System Value Set</u>.</li> </ul> </li> <li>• Deleted the exclusion for <u>Anaphylactic Reaction Due to Serum Value Set</u> (with date of service prior to October 1, 2011).</li> </ul>
Immunizations for Adolescents	<ul style="list-style-type: none"> <li>• <u>Meningococcal Value Set</u> was renamed <u>Meningococcal Vaccine Administered Value Set</u>.</li> <li>• <u>Tdap Value Set</u> was renamed <u>Tdap Vaccine Administered Value Set</u>.</li> <li>• <u>Td Value Set</u> was renamed <u>Td Vaccine Administered Value Set</u>.</li> <li>• <u>Tetanus Value Set</u> was renamed <u>Tetanus Vaccine Administered Value Set</u>.</li> <li>• <u>Diphtheria Value Set</u> was renamed <u>Diphtheria Vaccine Administered Value Set</u>.</li> </ul>

Measure Name	Changes
<b>Effectiveness of Preventive Care</b>	
Human Papillomavirus Vaccine for Female Adolescents	<ul style="list-style-type: none"> <li>• <u>HPV Value Set</u> was renamed <u>HPV Vaccine Administered Value Set</u>.</li> </ul>
Lead Screening in Children	<ul style="list-style-type: none"> <li>• No changes to this measure.</li> </ul>
Colorectal Cancer Screening	<ul style="list-style-type: none"> <li>• No changes to this measure.</li> </ul>
Breast Cancer Screening	<ul style="list-style-type: none"> <li>• Revised exclusion criteria so that two unilateral mastectomies must have service dates 14 or more days apart.</li> </ul>
<b>Effectiveness of Acute Care</b>	
Cervical Cancer Screening	<ul style="list-style-type: none"> <li>• <u>Hysterectomy Value Set</u> was renamed <u>Absence of Cervix Value Set</u>.</li> <li>• Added an example to step 2 of the numerator criteria in the Electronic Specification.</li> <li>• Clarified that cervical agenesis or acquired absence of cervix any time during the patient's history through December 31 of the measurement year meets exclusion criteria.</li> </ul>
Non-Recommended Cervical Cancer Screening in Adolescent Females	<ul style="list-style-type: none"> <li>• <u>Immunodeficiency Value Set</u> was renamed <u>Disorders of the Immune System Value Set</u>.</li> </ul>
Chlamydia Screening in Women	<ul style="list-style-type: none"> <li>• Revised value sets used for the event/diagnosis criteria to ensure that supplemental data (e.g., LOINC codes) are not used to identify the denominator.</li> <li>• Deleted <u>Chlamydia Tests Value Set</u> from the event/diagnosis criteria and added appropriate (e.g., CPT, UB Revenue) codes from these value sets to the <u>Sexual Activity Value Set</u>.</li> </ul>
Non-Recommended PSA-Based Screening in Older Men	<ul style="list-style-type: none"> <li>• First-year measure.</li> </ul>
Use of High-Risk Medications in the Elderly	<ul style="list-style-type: none"> <li>• No changes to this measure.</li> </ul>
Care for Older Adults	<ul style="list-style-type: none"> <li>• Clarified that a medication list, signed and dated by the appropriate practitioner type (prescribing practitioner or clinical pharmacist) meets criteria for medication review.</li> <li>• Revised medical record requirements for functional status assessment.</li> </ul>
Appropriate Treatment for Children With Upper Respiratory Infection	<ul style="list-style-type: none"> <li>• No changes to this measure.</li> </ul>
Appropriate Testing for Children With Pharyngitis	<ul style="list-style-type: none"> <li>• No changes to this measure.</li> </ul>
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis	<ul style="list-style-type: none"> <li>• No changes to this measure.</li> </ul>
Use of Imaging Studies for Low Back Pain	<ul style="list-style-type: none"> <li>• No changes to this measure.</li> </ul>

Measure Name	Changes
<b>Effectiveness of Chronic Care</b>	
Persistence of Beta-Blocker Treatment After a Heart Attack	<ul style="list-style-type: none"> <li>Removed “discharged alive” throughout the specification.</li> <li>Clarified the patient inclusion criteria for health plans.</li> <li>Clarified the event/diagnosis criteria to state that professional claims may not be used to identify readmissions or transfers.</li> <li>Defined <i>180-day measurement interval</i>.</li> </ul>
Controlling High Blood Pressure	<ul style="list-style-type: none"> <li>Revised the definition of adequate control to include two different BP thresholds based on age and diagnosis.</li> <li>Added a Diabetes Flag and corresponding value sets in the event/diagnosis criteria.</li> <li><u>Hypertension Value Set</u> was renamed <u>Essential Hypertension Value Set</u>.</li> <li>Revised exclusion criteria for nonacute inpatient admissions.</li> <li>Deleted the <u>Nonacute Care Value Set</u>; organizations use facility and proprietary coding to identify nonacute inpatient admissions.</li> <li>Revised the numerator to include the different BP thresholds in the Medical Record Specification.</li> </ul>
Comprehensive Ischemic Vascular Disease	<ul style="list-style-type: none"> <li>Retired the <u>Lipid Panel</u> and <u>LDL-C Control</u> indicators and the BP &lt;140/80 mm Hg threshold.</li> </ul>
Comprehensive Adult Diabetes Care	<ul style="list-style-type: none"> <li>Retired the <u>LDL-C screening</u>, <u>LDL-C control (&lt;100 mg/dL)</u> and <u>BP control (&lt;140/90 mm Hg)</u> indicators.</li> <li>Revised the ED visit requirement for claim/encounter data in the event/diagnosis criteria</li> <li>Added dapagliflozin to the description of “Sodium glucose cotransporter 2 (SGLT2) inhibitor” in Table CDC-A.</li> <li>Added albiglutide to the description of “Glucagon-like peptide-1 (GLP1) agonists” in Table CDC-A.</li> <li><u>CHF Value Set</u> was renamed <u>Chronic Heart Failure Value Set</u>.</li> <li>Clarified the requirements for a foot examination.</li> <li><u>Gestational or Steroid-Induced Diabetes Value Set</u> was renamed <u>Diabetes Exclusions Value Set</u>.</li> </ul>
Use of Appropriate Medications for People With Asthma	<ul style="list-style-type: none"> <li>Clarified the definition of <i>injection dispensing event</i>.</li> <li>Clarified step 2 of the event/diagnosis criteria.</li> </ul>
Medication Management for People With Asthma	<ul style="list-style-type: none"> <li>Clarified the definition of <i>injection dispensing event</i>.</li> <li>Clarified step 2 of the event/diagnosis criteria.</li> </ul>
Asthma Medication Ratio	<ul style="list-style-type: none"> <li>Clarified the definition of <i>injection dispensing event</i>.</li> <li>Clarified the definition of <i>units of medication</i>.</li> <li>Clarified step 2 of the event/diagnosis criteria.</li> </ul>
Use of Spirometry Testing in the Assessment and Diagnosis of COPD	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>
Pharmacotherapy Management of COPD Exacerbation	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>

Measure Name	Changes
<b>Effectiveness of Chronic Care</b>	
Follow-Up After Hospitalization for Mental Illness	<ul style="list-style-type: none"> <li>Removed “discharged alive” from the event/diagnosis criteria.</li> <li>Clarified that professional claims may not be used to identify readmission discharges or discharges from the facility to which the patient was transferred.</li> <li>Clarified that discharges followed by readmission or direct transfer to a nonacute facility are excluded (regardless of principal diagnosis).</li> <li>Deleted the Nonacute Care Value Set; organizations use facility and proprietary coding to identify inpatient readmissions and direct transfers.</li> </ul>
Antidepressant Medication Management	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	<ul style="list-style-type: none"> <li>Revised the “ED visit” requirement for claim/encounter data in step 2 of in the event/diagnosis criteria.</li> </ul>
Diabetes Monitoring for People With Diabetes and Schizophrenia	<ul style="list-style-type: none"> <li>Revised the “ED visit” requirement for claim/encounter data in step 2 of in the event/diagnosis criteria.</li> <li><u>Gestational or Steroid-Induced Diabetes Value Set</u> was renamed <u>Diabetes Exclusions Value Set</u>.</li> </ul>
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>
Adherence to Antipsychotic Medications for Individuals With Schizophrenia	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>
Use of Multiple Concurrent Antipsychotics in Children and Adolescents	<ul style="list-style-type: none"> <li>First-year measure.</li> </ul>
Metabolic Monitoring for Children and Adolescents on Antipsychotics	<ul style="list-style-type: none"> <li>First-year measure.</li> </ul>
Follow-Up Care for Children Prescribed ADHD Medication	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>
Osteoporosis Management in Women Who Had a Fracture	<ul style="list-style-type: none"> <li>Revised the age criteria to add an upper age limit.</li> <li>Extended the look-back period to two years for exclusions due to previous bone-mineral density testing.</li> <li>Clarified that women who had an active prescription during the specified time frame in step 4 meet exclusion criteria.</li> <li>Removed “estrogens” from the list of osteoporosis therapies.</li> <li>Removed “pathological fractures” as fractures used to identify the event/diagnosis for the Eligible Population.</li> <li>Removed “single-photon absorptiometry” and “dual-photon absorptiometry” from the list of eligible bone density tests.</li> </ul>
Disease Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>

Measure Name	Changes
<b>Effectiveness of Chronic Care</b>	
Annual Monitoring for Patients on Persistent Medications	<ul style="list-style-type: none"> <li>Retired the <i>Annual monitoring for patients on anticonvulsants</i> rate.</li> <li>Revised the numerator for the ACE inhibitors and ARB, digoxin and diuretics rates to no longer allow a blood urea nitrogen therapeutic monitoring test to count as evidence of annual monitoring.</li> <li>Revised the numerator for the digoxin rate to add monitoring of serum digoxin level.</li> </ul>
Potentially Harmful Drug-Disease Interactions in the Elderly	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>
Medication Reconciliation Post-Discharge	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>
<b>Access/Availability of Care</b>	
Adults' Access to Preventive/ Ambulatory Health Services	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>
Children's and Adolescents' Access to Primary Care Practitioners	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>
Prenatal and Postpartum Care	<ul style="list-style-type: none"> <li>Reversed steps 6 and 7 in the diagram.</li> <li>Removed the note allowing registered nurses to conduct prenatal and postpartum visits.</li> <li>Clarified in the <i>Note</i> section that LMP may not be used to determine the first trimester.</li> </ul>
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	<ul style="list-style-type: none"> <li>Replaced "facility code" with "inpatient discharge" in the event/diagnosis criteria.</li> <li>Clarified that an inpatient admission in combination with a diagnosis of AOD meets criteria when identifying initiation and engagement.</li> <li>Clarified that initiation events may not include inpatient detoxification or detoxification codes.</li> <li>Clarified that the patient is removed from the denominator for both indicators if the initiation event was an inpatient stay with a discharge date after December 1 of the measurement year.</li> </ul>
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics	<ul style="list-style-type: none"> <li>First-year measure.</li> </ul>
<b>Utilization</b>	
Frequency of Ongoing Prenatal Care	<ul style="list-style-type: none"> <li>Added a note to the description clarifying that the <i>Guidelines for Physician Effectiveness of Care Measures</i> must be followed when calculating this measure.</li> <li>Removed the note allowing registered nurses to conduct prenatal visits.</li> </ul>
Well-Child Visits in the First 15 Months of Life	<ul style="list-style-type: none"> <li>Clarified that complete well-child visits must be on different dates of service for the numerators in the Medical Record Specification.</li> </ul>
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>
Adolescent Well-Care Visits	<ul style="list-style-type: none"> <li>No changes to this measure.</li> </ul>